Abstract
Objective: To explore the targeting effect of PLGA-NP and iRGD co-administration with PTXPLGA NP (PTX-PLGA + iRGD) on colorectal cancer.
Methods: Whether PLGA-NP co-administration with iRGD peptide could show effective tumor-targeting ability in contrast to with PLGA-NP in colorectal cancer mice models was evaluated. Moreover, the chemotherapeutics Paclitaxel (PTX) was loaded into the PLGA-NP to impart anti-tumor efficiency to the PTX-PLGA. Whether iRGD co-administration with PTX-PLGA NP (PTX-PLGA + iRGD) in colorectal cancer models enabled PTX to achieve better anti-tumor efficiency and biocompatibility was further assessed.
Results: The targeting ability of PLGA-NP was enhanced in cell experiment and colorectal cancer mice models by co-administration of iRGD. As a result, PTX-PLGA + iRGD achieved better anti-tumor efficacy than PTX and PTX-PLGA.
Conlusion: The nanocarrier based on PLGA with specific targeting ability could promote the clinical application of various chemotherapeutics similar to PTX. The combination of drug-loaded nanoparticles and iRGD could develop into a promising drug delivery system.
Keywords: Nanocarrier, paclitaxel, targeting ability, anti-tumor efficiency, colorectal cancer, iRGD.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[http://dx.doi.org/10.1016/j.clcc.2018.01.010] [PMID: 29486916]
[http://dx.doi.org/10.3748/wjg.v23.i26.4675] [PMID: 28765689]
[PMID: 27483631]
[http://dx.doi.org/10.1016/S0378-5173(01)00986-3] [PMID: 11879753]
[http://dx.doi.org/10.1016/0165-6147(92)90048-B] [PMID: 1350385]
[http://dx.doi.org/10.1016/j.ijpharm.2017.05.016] [PMID: 28501439]
[http://dx.doi.org/10.1016/j.ijpharm.2011.08.052] [PMID: 21920419]
[http://dx.doi.org/10.1016/j.ijpharm.2017.05.063] [PMID: 28576551]
[http://dx.doi.org/10.1021/acs.langmuir.8b00411] [PMID: 29676924]
[http://dx.doi.org/10.1016/j.ejpb.2008.11.010] [PMID: 19070661]
[http://dx.doi.org/10.1016/j.drudis.2006.07.005] [PMID: 16935749]
[http://dx.doi.org/10.1126/scitranslmed.aad6645]] [PMID: 26582895]
[http://dx.doi.org/10.2174/138920021131400105] [PMID: 24016112]
[http://dx.doi.org/10.1016/j.ccr.2009.10.013] [PMID: 19962669]
[http://dx.doi.org/10.1126/science.1183057] [PMID: 20378772]
[http://dx.doi.org/10.1016/j.biomaterials.2014.06.042] [PMID: 25023394]
[http://dx.doi.org/10.2217/nnm.15.106] [PMID: 26355733]
[http://dx.doi.org/10.1016/j.biomaterials.2016.07.023] [PMID: 27472162]
[http://dx.doi.org/10.1016/j.jconrel.2015.05.246] [PMID: 27005108]
[http://dx.doi.org/10.1016/j.nano.2007.03.003] [PMID: 17468055]
[http://dx.doi.org/10.1177/0885328218809019] [PMID: 30388386]
[http://dx.doi.org/10.1200/JCO.2002.20.5.1167] [PMID: 11870157]
[http://dx.doi.org/10.1016/S1470-2045(14)71207-0] [PMID: 25601342]
[http://dx.doi.org/10.1016/S0959-8049(01)00171-X] [PMID: 11527683]
[http://dx.doi.org/10.1517/14740338.6.5.609] [PMID: 17877447]
[http://dx.doi.org/10.2174/1567201811666140609154949] [PMID: 24909147]
[http://dx.doi.org/10.1016/j.ijpharm.2018.02.007] [PMID: 29427746]
[http://dx.doi.org/10.1016/j.jconrel.2005.09.034] [PMID: 16289422]
[http://dx.doi.org/10.1016/j.jconrel.2009.04.024] [PMID: 19409432]
[http://dx.doi.org/10.1016/j.biomaterials.2013.04.025] [PMID: 23639530]
[http://dx.doi.org/10.1016/j.ijpharm.2014.05.032] [PMID: 24858391]
[http://dx.doi.org/10.1073/pnas.0908201106] [PMID: 19805273]
[http://dx.doi.org/10.1158/1078-0432.CCR-10-0005] [PMID: 20538762]
[http://dx.doi.org/10.1021/bi101662j] [PMID: 21247217]